Volastra raises $12M seed led by Polaris to shut down metastasis

Volastra aims to halt cancer metastasis by targeting chromosomal instability

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis.

Polaris Partners led the seed round on Tuesday with participation from Droia Oncology Ventures, the Global Health Sciences Fund from Quark Venture LP and GF Securities, and Arch Venture Partners.

“The act of being chromosomally unstable is driving metastasis, and that

Read the full 703 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers